A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody, C44Mab-108
[post]
2022
unpublished
CD44 has been known as a marker of tumor initiating cells, and plays pro-tumorigenic functions in many cancers. The splicing variants play critical roles in malignant progression of cancers by promoting the stemness, cancer cell invasion or metastasis, and resistance to chemo- and radiotherapy. To understand each CD44 variant (CD44v) function is essential to know the property of cancers and establishment of the therapy. However, the function of the variant 4-encoded region has not to be
doi:10.20944/preprints202212.0392.v1
fatcat:oir6b6dbc5dyhb7hhtcybctjti